BioMarin Pharmaceuticals BMRN Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's other working capital?
- BioMarin Pharmaceuticals (BMRN) reported other working capital of $5.37M in Q1 2026.
- How has BioMarin Pharmaceuticals's other working capital changed year-over-year?
- BioMarin Pharmaceuticals's other working capital increased by 324.2% year-over-year, from $1.27M to $5.37M.
- What is the long-term trend for BioMarin Pharmaceuticals's other working capital?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's other working capital has grown at a 31.3% compound annual growth rate (CAGR), from $2.04M to $4.63M.
- What does other working capital mean?
- The net change in miscellaneous short-term operating assets and liabilities.
- How do you interpret other working capital?
- Fluctuations often represent timing differences in accruals or prepayments; consistent negative trends may indicate rising operational friction.
- How does other working capital compare across companies?
- Varies widely by industry; usually a small component of operating cash flow for pharmaceutical companies.